Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Dabur India Ltd. Interim / Quarterly Report 2021

May 7, 2021

59077_rns_2021-05-07_88c1a732-d586-4f1c-afef-22fbf184e400.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

Ref: SEC/SE/2021-22 ed Date: May 7, 2021 India Ltd.

Scrip Symbol: NSE- DABUR, BSE Scrip Code: 500096

To,

BSE Ltd. Exchange Plaza, 5th Floor Dalal Street, Mumbai- 400001 Bandra (I), Mumbai - 400051

Corporate Relation Department National Stock Exchange of India Ltd. Phiroze Jeejecbhoy Towers Plot No. C/1, G Block Bandra - Kurla Complex

Sub: Investors Communication

Dear Sir,

In compliance of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to enclose a copy of Investors Communication being issued by the company today for your records.

This is for your information and records.

Thanking You,

Yours faithfully,

For Dabur India Limited

Executive V P (Finance) and Company Secretary

Encl: as above

DABUR INDIA LIMITED, Punjabi Bhawan, 10, Rouse Avenue, New Delhi-110 002, Tel.: +91 11 71206000 Fax: +91 11 23222051 Regd. Office: 8/3, Asaf Ali Road, New Delhi - 110 002 (India) PAN: AAACD0474C, CIN: L24230DL1975PLCO07908, Email: [email protected], Website: www.dabur.com

Q4 FY21 and FY21 – Results Presentation

7th May 2021

Agenda

Agenda

FY21 – Performance Summary

Consolidated Revenue Growth 9.9%
India FMCG Growth 14.7%
International Business Growth 3.4%
Operating Profit Growth 11.7%
Consolidated PAT Growth 17.2%

FY21 – Financials

  • Consolidated PAT reported an increase of 17.2% with PAT margin improving by 110 bps, touching 17.7%
  • Effective tax rate for Consol business increased from 16.2% to 17.6% on account of country mix

Domestic FMCG Growth – By Verticals – FY21

Innovation (Domestic Business) – FY21

International Business – FY21 Performance

Innovation (International Business) – FY21

Agenda

Q4 FY21 – Performance Summary

Consolidated Revenue Growth 25.3%
India Standalone Growth 30.3%
International Business Growth 19.4%
Operating Profit Growth 25.6%
Consolidated PAT Growth 34.4%

Q4 FY21 – Financials

  • Consolidated PAT reported an increase of 34.4% with PAT margin touching 16.2%
  • Effective tax rate for Consol business decreased from 17.2% to 16.5% on account of

Q4 FY20 Q4 FY21

Domestic FMCG Growth – By Verticals – Q4 FY21

International Business – Q4 FY21 Performance

Agenda

Healthcare – Q4 FY21

Health
Supplements
Digestives OTC Ethicals
Growth % 17.7% 20.0% 34.0% 39.1%
Dabur Chyawanprash

recorded strong growth
despite it being off-season
Pudin
Hara portfolio posted

double-digit growth in Q4
FY21
Driven by strong growth in

Lal Tail and Shilajit
Portfolio
Ethicals
grew in strong

double digits on the back of
distribution expansion,
Category
Highlights
Market share in Chyawanprash

category increased by ~170 bps
Hajmola
portfolio saw strong

recovery in Q4 FY21 on the back
of improvement in mobility and

NPDs like Dabur Health
Drops, Health Juices and
other immunity boosting
products added to the
visibility initiatives and
activations

Market share in Honey category
increased by ~230 bps
out-of-home consumption momentum of the portfolio

Dabur Chyawanprakash – for Diabetics New TVC with Parineeti Chopra for Dabur Pudin Hara

Dabur Rheumatil Spray and Dabur Jamun Neem Karela Juice – New Products Launched 16

Home and Personal Care – Q4 FY21

Oral Care Hair Oils Shampoo Home Care Skin & Salon
Growth % 42.1% 24.6% 33.4% 24.3% 37.9%
Category
Highlights
Red Toothpaste

continued to see good
demand momentum
Witnessed a smart

broad based recovery
Shampoos portfolio

registered strong growth
Odonil
reported strong

growth although Air
freshener category
Driven by strong

growth across brands
Meswak
and Babool

Franchise also reported
robust double-digit
Perfumed oils and

coco oils portfolios
reported double digit
growth
Market share in

shampoo category
increased by ~70 bps
continued to be impacted
being more discretionary
in nature. Odonil's
MS
improved by ~90 bps
Gulabari
and Fem saw

sequential improvement
as mobility and outdoor
activity increased
growths

Toothpaste market
share improved by
~120 bps
Market share

improved by ~70 bps

Bottle saliency
continues to see
improvement
Odomos
witnessed

recovery and MS
increased ~130 bps

Dabur Red Toothpaste – Take good care of teeth but keep them hidden behind a mask till we all are safe

Vatika Enriched Hair Oils Range

Food and Beverage – Q4 FY21

Beverages Foods
Growth % 27.1% 36.1%
Category
Highlights

Beverage business witnessed a smart recovery during Q4
despite HORECA business remaining under pressure
Market share of Real in JNSD (Juices, Nectar and Still Drinks)

increased by 80 bps

In-home and out-of-home portfolios registered strong double-digit
growths
Recent launches of Real Mango Drink in PET, Real Frappe and Real Apple

Mini showed good traction
Hommade
brand continued to perform well driven by increased in home

consumption
Recent launches like chutneys & pickles added to the growth momentum

Real Hydration Range – New Communication

Real Frappe – New Communication Activ Coconut Water – Influencer Activity

Agenda

Dividend Update

Interim
Dividend
Final
Dividend
Total
Dividend
Dividend per share (INR) 1.75 3.0 4.75
Dividend % 175% 300% 475%
Total dividend
(INR cr)
309.30 530.22 839.52

Dividend policy changed with Payout Ratio at 50% of Dabur India Ltd's Consolidated Profit after Tax (vs 40% of Consolidated PAT or 50% of Standalone PAT earlier)

Annexure

Consolidated Profit and Loss Statement

figures
All
are in
INR
cr
Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%)
Revenue from operations 2,336.8 1,865.4 25.3% 9,561.7 8,703.6 9.9%
Other Income 85.0 75.7 12.2% 325.3 305.2 6.6%
Total Income 2,421.8 1,941.1 24.8% 9,886.9 9,008.8 9.7%
Material Cost 1,197.9 949.6 26.1% 4,789.0 4,360.2 9.8%
of
%
Revenue
3%
51
50
9%
50
1%
50
1%
Employee expense 268.4 230.1 16.6% 1,033.5 947.7 9.0%
%
of
Revenue
11
5%
12
3%
10
8%
10
9%
Advertisement and publicity 154.2 100.2 53.8% 784.4 650.0 20.7%
of
%
Revenue
6
6%
5
4%
8
2%
7
5%
Other Expenses 274.0 233.2 17.5% 952.2 953.2 (0.1%)
of
%
Revenue
11
7%
12
5%
10
0%
0%
11
Operating Profit 442.4 352.3 25.6% 2,002.6 1,792.4 11.7%
%
of
Revenue
18
9%
18
9%
20
9%
20
6%
EBITDA 527.4 428.1 23.2% 2,327.9 2,097.7 11.0%
%
of
Revenue
22
6%
22
9%
24
3%
24
1%
Finance Costs 8.6 8.6 0.7% 30.8 49.5 (37.8%)
Depreciation & Amortization 66.5 58.8 13.1% 240.1 220.5 8.9%
Profit before exceptional items, tax and share of 452.2 360.7 25.4% 2,057.0 1,827.7 12.5%
profit/(loss) from joint venture
of
%
Revenue
19
4%
19
3%
21
5%
21
0%
Share of profit / (loss) of joint venture (0.6) (0.4) 52.0% (1.0) (0.0) 10,028.4%
Exceptional item(s) 0.0 20.0 (100.0%) 0.0 100.0 (100.0%)
Tax Expenses 74.3 58.6 26.8% 361.1 279.7 29.1%
Net profit after tax and after share of profit/(loss) 377.3 281.6 34.0% 1,694.9 1,447.9 17.1%
from joint venture
of
%
Revenue
16
1%
15
1%
17
7%
16
6%
Non controlling interest (0.5) 0.4 (223.3%) 1.7 3.0 (44.3%)
Net profit for the period/year
of
%
Revenue
377.8
16
2%
281.2
15
1%
34.4% 1,693.3
17
7%
1,445.0
16
6%
17.2%

Standalone Profit and Loss Statement

All
figures
are in
INR
cr
Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%)
Revenue from operations 1,721.9 1,321.2 30.3% 7,184.7 6,309.8 13.9%
Other Income 70.5 67.1 5.2% 276.7 276.9 (73.6%)
Total Income 1,792.4 1,388.2 29.1% 7,461.4 6,586.7 13.3%
Material Cost 924.5 676.6 36.6% 3,696.8 3,244.7 13.9%
%
of
Revenue
53
7%
51
2%
51
5%
51
4%
Employee expense 166.5 133.6 24.6% 655.8 578.3 13.4%
%
of
Revenue
9
7%
10
1%
9
1%
9
2%
Advertisement and publicity 116.9 69.2 69.0% 643.5 514.3 25.1%
of
%
Revenue
6
8%
2%
5
9
0%
8
2%
Other Expenses 181.4 143.7 26.2% 629.4 591.8 6.4%
of
%
Revenue
10
5%
10
9%
8
8%
9
4%
Operating Profit 332.7 298.1 11.6% 1,559.2 1,380.8 12.9%
%
of
Revenue
19
3%
22
6%
21
7%
21
9%
EBITDA 403.2 365.2 10.4% 1,835.9 1,657.7 10.7%
%
of
Revenue
23
4%
27
6%
25
6%
26
3%
Finance Costs 3.0 2.6 14.6% 9.1 19.3 (52.6%)
Depreciation & Amortization 37.4 33.2 12.7% 143.4 129.9 10.4%
Profit before exceptional items, tax and share of
profit/(loss) from joint venture
362.8 329.3 10.1% 1,683.3 1,508.5 11.6%
of
%
Revenue
21
1%
24
9%
23
4%
23
9%
Exceptional item(s) 0.0 20.0 (100.0%) 0.0 100.0 (100.0%)
Tax Expenses 62.5 52.3 19.4% 301.4 238.1 26.6%
Net profit for the period/year 300.3 257.0 16.8% 1,381.9 1,170.4 18.1%
of
%
Revenue
17
4%
19
5%
19
2%
18
5%

Consolidated Balance Sheet

Particulars As at 31/03/2021
(Audited)
As at
31/03/2020
(Audited)
Particulars As at 31/03/2021
(Audited)
As at
31/03/2020
(Audited)
A
Assets
B
Equity and Liabilities
Non-current
1
1
Equity
assets (a)
Equity share capital
177 177
(a)
Property, plant and equipment
1,812 1,821 (b)
Other Equity
7,487 6,430
(b)
Capital work-in-progress
168 147 Equity attributable to shareholders of the Company 7,664 6,607
(c)
Investment property
50 52 Non Controlling Interest 37 36
(d)
Goodwill
336 336 Total equity 7,701 6,643
(e)
Other Intangible assets
45 44
(f)
Financial assets
2
Non-current liabilities
(i)
Investments
3,414 1,409 (a)
Financial liabilities
(ii)
Loans
17 20 (i)
Borrowings
134 175
(iii)
Others
86 528 (ii)
Other financial liabilities
1 1
(g)
Deferred tax assets
17 23 (b)
Provisions
63 63
(h)
Non-current tax assets (net)
4 1 (c)
Deferred tax liabilities (Net)
13 17
(i)
Other non-current assets
122 112 Total Non-current liabilities 211 256
Total Non-current assets 6,071 4,492 3
Current liabilities
2
Current assets
(a)
Financial liabilities
(a)
Inventories
1,730 1,380 (i)
Borrowings
356 304
(b)
Financial assets
(ii)
Trade payables
(i)
Investments
758 1,387 Due to micro and small
(ii)
Trade receivables
560 809 enterprises 118 0
(iii)
Cash and cash equivalents
229 167 Due to 1,802 1,480
(iv)
Bank Balances other than (iii) above
1,087 645 others
(v)
Loans
15 12 (iii)
Other financial liabilities
235 232
(vi)
Others
3 3 (b)
Other current liabilities
312 230
(c)
Current tax asset(net)
1 1 (c)
Provisions
188 166
(d)
Other current assets
554 462 (d)
Current tax Liabilities (Net)
85 47
(e)
Assets held for sale
0 0 Total Current liabilities 3,095 2,458
Total current assets 4,936 4,865
Total Equity and Liabilities 11,007 9,357
Total Assets 11,007 9,357

Standalone Balance Sheet

Particulars As at 31/03/2021
(Audited)
As at
31/03/2020
(Audited)
Particulars As at 31/03/2021
(Audited)
As at
31/03/2020
(Audited)
A
Assets
B
Equity and Liabilities
1
Non-current assets
1
Equity
(a)
Property, plant and equipment
1,131 1,061 (a)
Equity share capital
177 177
(b)
Capital work-in-progress
128 106 (b)
Other Equity
5,214 4,399
(c)
Investment property
47 48 Total equity 5,391 4,575
(d)
Other Intangible assets
26 25
(e)
Financial assets
2
Non-current liabilities
(i)
Investments
3,123 1,084 (a)
Financial liabilities
(ii)
Loans
10 12 (i)
Borrowings
20 25
(iii)
Others
86 403 (ii)
Other financial liabilities
1 1
(f)
Deferred tax assets
17 23 (b)
Provisions
56 55
(g)
Non-current tax assets (net)
4 1 (c)
Deferred tax liabilities (Net)
0 0
(h)
Other non-current assets
101 91 Total Non-current liabilities 76 80
Total Non-current assets 4,675 2,854
3
Current liabilities
2
Current assets
(a)
Financial liabilities
(a)
Inventories
1,114 809 (i)
Borrowings
158 89
(b)
Financial assets
(ii)
Trade payables
(i)
Investments
451 1,379 Due to micro and small enterprises 118 0
(ii)
Trade receivables
277 374 Due to others 1,370 1,030
(iii)
Cash and cash equivalents
11 6 (iii)
Other financial liabilities
161 156
Bank Balances other than (iii)
(iv)
822 521 (b)
Other current liabilities
73 46
above (c)
Provisions
134 123
(v)
Loans
2 (d)
Current tax Liabilities (Net)
27 5
(vi)
Others
8 9 Total Current liabilities 2,042 1,448
(c)
Current tax assets(net)
0 0
(d)
Other current assets
149 152 Total Equity and Liabilities 7,509 6,103
Total current assets 2,834 3,250
Total Assets 7,509 6,103

Breakdown of Revenue from Operations

All
figures
unless
otherwise
stated
in
INR
are
crores,
Q4 FY21 Q4 FY20 Y-o-Y (%) FY21 FY20 Y-o-Y (%)
Health Supplements 285 242 17.7% 1,589 1,115 42.5%
Digestives 104 87 20.0% 381 372 2.2%
OTC & Ethicals 151 110 36.9% 677 518 30.6%
Healthcare 541 440 22.9% 2,647 2,006 31.9%
Shampoo & Post Wash 54 40 33.4% 220 192 14.9%
Hair Oils 280 225 24.6% 1,051 1,057 (0.6%)
Hair Care 334 265 26.0% 1,272 1,249 1.8%
Oral Care 311 219 42.1% 1,238 1,005 23.2%
Home Care 89 72 24.3% 380 408 (6.8%)
Skin & Salon 78 57 37.9% 356 302 17.6%
HPC 813 613 32.6% 3,245 2,964 9.5%
Beverages 225 177 27.1% 826 888 (7.1%)
Foods 16 12 36.1% 63 54 17.0%
Food and Beverage (F&B) 241 189 27.6% 888 942 (5.7%)
Sales -
Domestic FMCG
1,594 1,241 28.4% 6,780 5,912 14.7%
Others (Guar, Fem Pharma, Exports, etc) 102 71 43.8% 374 348 7.7%
Revenue -
DIL Standalone
1,722 1,321 30.3% 7,185 6,310 13.9%
International 649 543 19.4% 2,511 2,430 3.4%
Retail 23 28 (18.6%) 57 125 (54.2%)
Inter Company Exports (Net) (57) (28) n.m. (192) (161) n.m.
Revenue from Operations -
Consolidated
2,337 1,865 25.3% 9,562 8,704 9.9%

For more information and updates, visit: http://www.dabur.com/in/en-us/investor